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Glycinamide riboneucleotide formyltransferase (GARFT) is an
essential enzyme in the pathway for de novo purine synthesis.
Most normal tissues, with the exception of liver and activated 
T-lymphocytes, derive purines primarily through the salvage
pathway. Tumour cells, in contrast, generally have elevated
activity of the de novo pathway, and often have decreased activity
of purine salvage enzymes, suggesting that they rely primarily
upon de novo purine biosynthesis (Jackson and Harkrader, 1981).
Selective inhibitors of purine biosynthesis may therefore have a
different toxicity profile and possibly antitumour selectivity
compared with other classes of antimetabolites. 
The first selective GARFT inhibitor tested in clinical trials
was (6R)-5,10-dideazatetrahydrofolate (lometrexol). This agent
demonstrated objective antitumour activity in phase I studies but
with unexpected toxicity, namely myelosuppression and mucositis
(Ray et al, 1993). This was attributed to accumulation of polyglu-
tamate metabolities in normal tissues and was ameliorated by the
coadministration of either folic acid or folinic acid (Laohavinij et
al, 1996; Sessa et al, 1996). 
AG2034 is a novel and selective inhibitor of GARFT designed
with knowledge of the X-ray crystal structures of the E. coli
enzyme and of the GARFT domain of the human enzyme.
Preclinical enzyme inhibition studies showed that AG2034 is a
potent inhibitor of GARFT and a good substrate for folylpolyglu-
tamate synthetase (FPGS), with similar potency to lometrexol.
AG2034 can enter cells utilizing the reduced folate carrier and
the membrane folate-binding protein. The agent has good anti-
tumour activity in a broad range of tumour cell lines and human
xenografts. Preclinical toxicological studies of AG2034 were
conducted in mice and dogs. The major target organs for toxicity
were the gastrointestinal tract and the bone marrow. Pre-treatment
of animals with a diet deficient in folates enhanced these effects.
When administered intravenously daily for 5 days the MTD of
AG2034 was 0.2 mg kg21 day21 in mice fed a low-folate diet,
compared with 40 mg kg21 day21 in mice fed a normal diet. Dogs
were found to be relatively more sensitive than mice to the effects
of AG2034. With the daily for 5 days schedule the no-effect-level
(NOEL) was 0.2 mg kg21 day21 in dogs and 3 mg kg21 day21 in
mice. With a single intravenous injection, the NOEL in dogs was
60 mg/m2. 
This phase I trial was initiated to evaluate AG2034 administered
to patients with refractory solid malignancies. Although there was
some evidence of schedule-dependent cytotoxicity in preclinical
studies, in the interests of safety, a once every three weeks
schedule was selected for this trial. The objectives of the study
were (1) to evaluate the safety and dose tolerance of AG2034
when given by intravenous bolus injection to patients with
advanced malignancy; (2) to study the pharmacokinetics and phar-
macodynamics of AG2034; and (3) to document any antitumour
effects of AG2034. Prior to commencing the study it was approved
by the Grampian Health Board and University of Aberdeen Joint
Ethical Committee. 
PATIENTS AND METHODS 
Eligibility criteria 
Patients with histologically proven solid malignancy, for which no
satisfactory treatment existed or against which established treat-
ments had failed, were considered candidates for the study. Other
eligibility criteria included: (1) WHO performance status 0, 1, or
2, (2) no prior chemotherapy within 4 weeks of study entry, (3) no
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radiotherapy, nitrosourea or mitomycin chemotherapy within 6
weeks of study entry, (4) satisfactory haematological and serum
chemistry parameters, (5) age at least 18 years, (6) life expectancy
of at least 3 months, and (7) written informed consent for the
study. Patients were excluded from the trial if they had any of the
following: (1) CNS disease which precluded informed consent, 
(2) severe co-existing medical condition, (3) evidence of bone
marrow involvement by tumour or bone marrow compromise from
previous anti-cancer therapy, (4) regular dietary folate supple-
ments, (5) haematological malignancy, (6) concurrent medication
with allopurinol or trimethoprim or other anticancer or experi-
mental therapy, (7) prior therapy with a GARFT inhibitor, or (8) if
they were pregnant, lactating, or unwilling to take reliable contra-
ception if applicable. 
Treatment studies 
This was an open label non-randomized phase I study with dose
escalation between cohorts of patients. The study was conducted
under the auspices of The Cancer Research Campaign, UK.
Agouron Pharmaceuticals Inc., La Jolla, California, supplied
AG2034, as a lyophilized powder, which was reconstituted with
4 ml water, resulting in a 5 mg ml21 solution. This was further
diluted in 0.9% saline to a volume of 10 ml prior to administration
as a 5 minute infusion. The starting dose of AG2034 was 1 mg/m2,
which was one sixtieth of the NOEL in dogs. Doses were repeated
at 3-week intervals provided drug-related non-haematological
toxicities had resolved and haematological parameters were
satisfactory (Hb ³ 10 g dl21, WCC ³ 4.0 ´ 109 l21, and platelets
³100´ 109 l21). Treatment was continued for a total of 6 cycles or
until there was objective evidence of disease progression, or the
development of toxicity precluding further therapy, or at the
request of the patient. No antiemetic or other prophylactic medica-
tion was given with the first cycle of AG2034 but subsequently
concurrent medication was administered as deemed appropriate by
the clinician. No dose modifications were planned and dose esca-
lation for individual patients was not permitted. There was no
attempt to ameliorate toxicities with folate supplements or
haematopoietic growth factors.
During the study patients were closely monitored, with weekly
clinic visits for physical examination, toxicity evaluation, and
blood sampling for full blood count and serum chemistry. Tumour
assessment, usually by CT scan, was performed prior to study
entry and after cycles 3 and 6 of AG2034. 
A minimum of 3 patients were recruited to each dose level and
if any of these patients experienced dose-limiting toxicity (DLT –
see below for definition) a further 3 patients were treated at that
dose level. Dose escalation was stopped when 2 or more members
of a cohort experienced DLT. Dose escalation followed a modified
Fibonacci scheme but was also guided by the toxicities observed
in a concurrent phase I study of AG2034 conducted in the US
using an identical schedule (Roberts et al, 2000). 
Tumour response and toxicity criteria 
Tumour response was assessed according to the criteria of the
CRC Phase I/II Trials Committee. Toxicities were graded
according to the NCIC-CTG Expanded Common Toxicity
Criteria. DLT was defined by the occurrence of any of the
following: grade 4 neutropaenia or thrombocytopaenia, ³ grade 3
anaemia, emesis uncontrolled by aggressive anti-emetic therapy,
or other grade 3 non-haematological toxicities. The maximum
tolerated dose was defined as the dose level associated with DLT
in at least 2 of 6 patients. 
Pharmacokinetic study and analysis 
Blood samples were collected from all patients for estimation of
parent compound and metabolites. Samples were taken before
drug administration in cycle one, and following drug administra-
tion at 5 and 30 minutes, at 1, 2, 4, 6, 8, 12, 24, 48, 72 and 96
hours, and weekly therafter. During the third cycle of AG2034,
blood samples were taken at 5 and 30 minutes, and 1 and 24 hours
after treatment. Subsequently weekly samples were taken until the
patient was withdrawn from the trial. Plasma concentrations of
AG2034 were measured using an ELISA assay (McLeod et al,
2000) and pharmacokinetic analyses were conducted using
ADAPT II software (D’Argenio and Schumitzky, 1979). 
RESULTS 
28 patients were enrolled into the study. Patient characteristics are
listed in Table 1. The majority of patients were under the age of 65
years with good performance status. Metastatic colorectal cancer
was the most frequent diagnosis, and while 24 patients had
received prior chemotherapy only one patient had received more
than 2 previous cytotoxic regimens. 20 patients had more than one
site of disease. 
All patients were assessable for toxicity. A total of 78 cycles of
treatment were delivered over the dose range 1–11 mg/m2, with a
median of 3 cycles per patient (range 1–6). The treatment delivered
is summarized in Table 2. Cohorts of patients were treated at
escalating doses at 1, 1.5, 2.25, 3.4 and 5 mg/m2. Recruitment of
patients to the next two dose levels (7.5 and 11 mg/m2) was stopped
early following the occurrence of severe gastrointestinal toxicity at
these dose levels in the parallel US phase I study of AG2034. In
addition, preliminary analysis of pharmacokinetic data suggested
accumulation of AG2034 through cycles 1–3. A cohort of 6
patients was then treated at the intermediate dose of 6 mg/m2. 
Table 1 Patient characteristics 
Number of patients 28 
Male : female 18:10 
Age median 59.5 
range 34–76 
Performance status 
01  
1 24 
23  
Primary tumour site 
Colorectal 13 
Mesothelioma 4 
Unknown primary 2 
Ovary 1 
Carcinoid 1 
Cervix 1 
Gallbladder 1 
Hepatoma 2 
Melanoma 1 
Pancreas 1 
Sarcoma 1 
Previous treatment 
Chemotherapy 24 
More than one chemotherapy regimen 10 
Radiotherapy 7 Toxicities 
The major toxicities observed are summarized in Tables 3 and 4.
Gastrointestinal and haematological toxicities were reported at all
dose levels. Stomatitis and diarrhoea that were dose limiting
occurred in 2 out of 6 patients treated at 6 mg/m2, defining this as
the MTD. Stomatitis started 1–17 days after treatment with
AG2034 (median 5 days) and resolved after 1–26 days (median
11.5 days). Diarrhoea started 1–21 days after treatment (median
6.5 days) and resolved after 1–17 days (median 8 days).
Symptomatic treatment with loperamide was used throughout the
study. There was evidence of cumulative gastrointestinal toxicity
(Table 5). Grade 2 or worse mucositis was not seen until cycle 3 of
AG2034 in 4 of the 5 affected patients, usually preceded by milder
toxicity with the first two cycles. No attempt was made to modify
these toxicities with folic acid supplements. 
Haematological toxicities occurred sporadically throughout
the study but no patients had dose-limiting myelosuppression
(Table 4). The majority of patients experiencing thrombocyto-
penia or neutropenia received AG2034 at a dose of 5 mg/m2 or
more. There was no clear evidence of cumulative myelotoxicity
during the study. Other minor toxicities occurred infrequently,
including myalgia, neurosensory changes, and anorexia.
Significant (grade 2) malaise and lethargy were reported by 4 of
the 6 patients treated at 6 mg/m2. Two patients had infections
related to AG2034, one after cycle 2 at 7.5 mg/m2, the other after
cycle 1 at 11 mg/m2. These were associated with only grade 1
neutropenia and both resolved with antibiotic therapy. One patient
treated at the first dose level had grade 2 sensory peripheral
neuropathy for several days after cycles 1 and 3. This patient had
received two prior courses of chemotherapy, one of which
included oxaliplatin. However no other patients in the study had
similar symptoms although several patients had received prior
platinum-based chemotherapy. 
One patient had a dose delay (one week) and dose reduction
(from 6 mg/m2 to 5 mg/m2) because of grade 3 diarrhoea during
cycle 2. This was done after consultation with the CRC and
Agouron. Grade 3 diarrhoea recurred during cycle 3 and treatment
was discontinued. Another patient had a treatment delay of
6 days because of grade 2 thrombocytopenia after cycle 2 (dose 7.5
mg/m2). Dose reductions were not applied in any other patients. 
Tumour response 
No objective tumour responses were observed in the study. 18
patients had documented disease progression and two patients had
stable disease during treatment with AG2034. Treatment was
withdrawn in two cases because of unacceptable toxicity, two
patients declined further treatment, one patient developed bowel
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Table 3 Gastrointestinal toxicities 
Dose (mg/m2) Number of patients Mucositis Diarrhoea Nausea Vomiting 
2342 34 2 3 42  3 4  
1.0 3 0a 0 0 00 0 0  00 10 0  
1.5 3 0 0 0 0 0 0 0 0 0 0 0 0 
2.25 3 0 0 0 1 0 0 0 0 0 0 0 0 
3.4 4 0 0 0 0 0 0 1 0 0 0 0 0 
5.0 3 0 0 0 0 0 0 1 0 0 1 0 0 
6.0 6 1 1 1 1 1 0 1 0 0 1 0 0 
7.5 4 1 1 0 0 0 0 1 0 0 1 1 0 
11.0 2 0 0 0 1 0 0 2 0 0 0 1 0 
aData refer to the worst toxicity grade using the Expanded Common Toxicity Criteria (CTC), recorded for each patient at any cycle of AG2034. 
Table 4 Haematological toxicities 
Dose (mg/m2) Number of patients Neutropenia  Thrombocytopenia Anaemia 
23 42 3 4 2 3 4  
1.0 3 0a 0 0 0 0 0 1 0 0 
1.5 3 1 0 0 0 0 0 0 0 0 
2.25 3 0 0 0 0 1 0 1 0 0 
3.4 4 0 0 0 0 0 0 1 0 0 
5.0 3 0 1 0 1 0 0 1 0 0 
6.0 6 0 0 0 1 0 0 2 0 0 
7.5 4 0 1 0 1 1 0 2 1 0 
11.0 2 1 0 0 0 0 0 0 0 0 
aData refer to the worst CTC grade recorded for each patient at any cycle of AG2034. 
Table 2 Dose levels and number of cycles of AG2034 delivered 
Dose level Number of Number of Actual dose of AG2034
(mg/m2) patients cycles Median (range) mg 
1 3 3, 4, 6 1.70 (1.50–2.20) 
1.5 3 3, 5, 3 2.50 (2.30–3.00) 
2.25 3 4, 3, 2 3.15 (2.85–3.94) 
3.4 4 1, 1, 2, 3 6.02 (5.50–6.30) 
5 3 3, 3, 3 9.40 (8.95–10.00) 
6 6 3, 1, 3, 3, 3, 3 11.19 (9.40–13.80) 
7.5 4 4, 1, 3, 3 15.75 (14.80–16.50) 
11 2 1, 1 21.73 (20.35–23.10) Novel folate analogue AG2034 311
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obstruction necessitating laparotomy, and another required pallia-
tive radiotherapy. 
Pharmacokinetics 
AG2034 plasma concentrations were measured using an ELISA
assay (McLeod et al, 2000). The assay has a linear range from
1–500 ng ml21 and an inter-assay coefficient of variation of
6.7–8.2%. Metabolites are not detected by the ELISA. AG2034
area under the concentration–time curve (AUC) was determined
for each patient using the trapezoidal rule. Non-compartmental
pharmacokinetic analysis was restricted to the first 24 hours after
injection (AUC0–24), to allow better comparison between different
cycles of study drug. AG2034 pharmacokinetics were evaluable in
25 patients receiving 1–11 mg/m2 as a bolus injection. AG2034
AUC0–24 demonstrated a linear relationship with dose (r2 = 0.80),
with considerable variability in plasma drug exposure at each dose
level (Table 6). There was evidence of drug accumulation, as the
AG2034 AUC0–24 increased from cycle 1 to 3 in 10/10 patients in
whom samples were available for both cycles (median increase
184%, range 20% to 389%). 
A more detailed pharmacokinetic and pharmacodynamic analysis
of AG2034 has been produced by pooling data from this study with
those from 29 patients treated in the US study (McLeod et al, 2000).
Briefly the elimination of AG2034 was triphasic, with median
values for t1/2a 8.7 min, t1/2b 72.6 min, and t1/2g 364.2 min. The
systemic clearance of AG2034 ranged from 9.4–144.5 ml/min/m2,
and the volume of distribution was 1.2–7.6 litres/m2. 
DISCUSSION 
This report describes the first clinical experience with the GARFT
inhibitor AG2034. As predicted from both preclinical data and
previously reported clinical experience with lometrexol, the dose-
limiting toxicities of this agent were stomatitis and diarrhoea.
Table 6 Pharmacokinetic data 
Dose (mg/m2) Number of patients AUC cycle 1 AG2034 
(mg ml min21)a 
1 3 8.2 (6.1–10.7) 
1.5 3 17.3 (16.7–19.7) 
2.25 3 38.3 (27.3–77.2) 
3.4 3 47.6 (42.2–78.6) 
5 3 143.8 (107.1–191.7) 
6 6 140.7 (115.4–255.1) 
7.5 2 95.3, 127.1 
11 2 290.7, 323.2 
aAUC data is presented as the median and range. Individual data are
presented for the dose levels with only two data sets. 
Stomatitis 
 Cycle number
Number of
cycles
received
Number of
cycles
received
Dose
level
(mg/m2)
3
4
6
1
2
3
1.00
Diarrhoea
Cycle number
3
5
3
4
5
6
1.50
4
3
2
7
8
9
2.25
3
3
3
14
21
22
5.00
3
1
3
3
3
3
23
24
25
26
27
28
6.00
1
1
2
3
10
11
12
13
3.4
1
1
2
3
10
11
12
13
7.50
1
1
18
19
11.00
12345
G1
G1
G1 G1
G1 G1 G1
G1 G1 G1 G1
G1
G1 G2
b G1
G1
G1
G3 G1
G1
G1 G2 G1
G3 G1
G3 G4a
G1 G1
G1 G2
G2 G1
G3 G3
G1
G1
G2
G1
G1
6123456
G = worst CTC toxicity Grade reported by the patient during this cycle. aDose delayed by one week and reduced to 5 mg/m2. bDose delayed by one week
because of thrombocytopenia. 
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These were accompanied by significant levels of myelosuppression,
nausea and vomiting. For AG2034, as for lometrexol, cumulative
toxicity appears to be a specific problem. However for AG2034 we
have shown that this is associated with accumulation of the parent
compound rather than toxic metabolites as in the case of lome-
trexol (Synold et al, 1998). 
Although the pharmacokinetics of this agent showed large
inter-patient variability, there was good correlation between dose
and AUC for AG2034 during cycle one, implying that non-
linearities in absorption or metabolism are not prominent during
the first treatment cycle, at least at the doses used in this study.
Previous studies with lometrexol have not provided pharmaco-
kinetic evaluation beyond the first cycle of therapy (Wedge et al,
1995). This study demonstrates increase in the AG2034 AUC0–24
over the three cycles evaluated. It suggests that altered AG2034
pharmacokinetics, with or without independent pharmaco-
dynamic effects, are implicated in the cumulative toxicity
observed with this agent. 
An MTD of 5 mg/m2 was established when AG2034 was given
on a 3-weekly schedule of administration. Pharmacodynamic
studies confirm the appropriateness of this dose. The estimated
median AUC with 5 mg/m2 is 131 580 ng ml21 min21 and in the
range(+/- 10%) around this value no patients experienced toxicity.
This contrasts with the 6 mg/m2 AUC of 157 900 ng ml21 min21 in
which range 2/4 patients had dose-limiting toxicity (McLeod, 2000).
Further dose exploration would have included a more frequent
schedule of administration, but drug accumulation precluded further
study without folate supplementation to reduce toxicities. Future
development of inhibitors to GARFT should focus on novel
compounds which are more potent and selective, and which do not
share problems of drug or metabolite accumulation. 
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